Jyong Biotech Ltd. Ordinary Shares (MENS)

The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.